AI Clinical Tools

Allen & Overy Shearman Sterling published guidance on April 14, 2026, addressing data provenance in AI-driven pharmaceutical R&D—a critical issue as drug developers race to cut costs and accelerate timelines. The firm's Q&A examines why datasets must be traceable, compliant, and legally defensible as biotech AI platforms accumulate vast data pools for therapy identification, protein pattern recognition, and clinical optimization. When major pharmaceutical companies acquire these AI capabilities, rigorous due diligence becomes essential to manage legal exposure, privacy violations, and intellectual property disputes.

The White House released the National Policy Framework for Artificial Intelligence on March 20, 2026, laying out legislative recommendations to establish uniform federal AI standards. The Framework targets six key areas: child protection, infrastructure investment, intellectual property safeguards, regulatory sandboxes for innovation, workforce development, and preemption of state AI laws deemed to impose "undue burdens." Rather than creating a new federal AI agency, the Framework directs Congress to leverage existing regulators—the FDA, CMS, and DOJ—for sector-specific oversight, particularly in healthcare. The recommendations stem from a December 2025 Executive Order directing the Commerce Department to evaluate state AI regulations and propose uniform federal policy.